Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CHUCNASDAQ:SNTINASDAQ:TILNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHUCCharlie's$0.11+10.0%$0.06$0.03▼$0.20$28.32M1.0465,048 shs419,251 shsSNTISenti Biosciences$5.00+2.7%$3.52$1.52▼$16.94$130.02M2.32782,658 shs35,535 shsTILInstil Bio$12.78-34.8%$18.18$9.62▼$92.00$83.82M1.75125,417 shs713,536 shsTNXPTonix Pharmaceuticals$17.82+3.7%$15.84$6.76▼$672.00$114.67M1.5773,517 shs803,517 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHUCCharlie's+14.29%0.00%+149.38%+88.32%-9.01%SNTISenti Biosciences+9.93%+25.52%+37.57%+3.18%+73.37%TILInstil Bio-4.43%+26.93%+6.81%-16.30%+85.00%TNXPTonix Pharmaceuticals+1.00%+9.42%-42.26%-55.13%-96.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHUCCharlie'sN/AN/AN/AN/AN/AN/AN/AN/ASNTISenti Biosciences2.8684 of 5 stars3.53.00.00.02.71.71.3TILInstil Bio2.1873 of 5 stars3.51.00.00.00.63.31.3TNXPTonix Pharmaceuticals1.8436 of 5 stars3.52.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHUCCharlie's 0.00N/AN/AN/ASNTISenti Biosciences 3.00Buy$10.00100.00% UpsideTILInstil Bio 3.00Buy$114.00792.02% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.003,182.83% UpsideCurrent Analyst Ratings BreakdownLatest CHUC, TIL, TNXP, and SNTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.002/13/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHUCCharlie's$16.25M1.74N/AN/AN/A∞SNTISenti Biosciences$2.56M50.79N/AN/A$15.02 per share0.33TILInstil BioN/AN/AN/AN/A$34.72 per shareN/ATNXPTonix Pharmaceuticals$10.09M11.36N/AN/A$5,751.80 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHUCCharlie's-$2.09MN/A0.00∞N/A-24.96%N/A-61.40%5/19/2025 (Estimated)SNTISenti Biosciences-$71.06M-$12.03N/AN/AN/AN/A-154.84%-77.42%5/8/2025 (Estimated)TILInstil Bio-$156.09M-$11.39N/AN/AN/AN/A-37.44%-25.08%5/9/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$2,535.85N/AN/AN/A-1,197.86%-163.95%-118.88%5/12/2025 (Estimated)Latest CHUC, TIL, TNXP, and SNTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23N/AN/AN/A$2.55 millionN/A5/9/2025N/ATILInstil Bio-$2.02N/AN/AN/AN/AN/A3/20/2025Q4 2024SNTISenti Biosciences-$3.13-$0.67+$2.46-$0.67$2.80 million$5.86 million3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/4/2025Q4 2024TILInstil Bio-$3.75-$1.82+$1.93-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHUCCharlie'sN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHUCCharlie'sN/A0.740.23SNTISenti BiosciencesN/A1.921.92TILInstil Bio0.4712.9012.90TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHUCCharlie's7.80%SNTISenti Biosciences25.73%TILInstil Bio60.56%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipCHUCCharlie's22.40%SNTISenti Biosciences10.70%TILInstil Bio46.50%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHUCCharlie's40257.41 million199.69 millionNot OptionableSNTISenti Biosciences426.00 million4.30 millionNot OptionableTILInstil Bio4106.56 million3.49 millionNo DataTNXPTonix Pharmaceuticals506.44 million1.87 millionNot OptionableCHUC, TIL, TNXP, and SNTI HeadlinesRecent News About These CompaniesWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 7.99%April 24 at 7:18 PM | aaii.comTonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025April 24 at 7:55 AM | globenewswire.comTonix Pharmaceuticals (TNXP) to Present at World Vaccine CongressApril 23 at 3:19 PM | gurufocus.comTonix Pharmaceuticals (TNXP) Falls Despite Market UpturnApril 23 at 3:19 PM | gurufocus.comTonix Pharmaceuticals to Present at World Vaccine Congress Washington 2025 on Novel Mpox VaccineApril 16, 2025 | quiverquant.comTonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025April 16, 2025 | globenewswire.comWhy Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday?April 10, 2025 | insidermonkey.comTonix Pharmaceuticals, Makana to announce collaboration research agreementApril 9, 2025 | msn.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 10.75%April 9, 2025 | aaii.comTonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation StudiesApril 9, 2025 | globenewswire.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 18.09%April 8, 2025 | aaii.comWhat is Zacks Small Cap's Estimate for TNXP Q1 Earnings?April 8, 2025 | marketbeat.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...April 7, 2025 | gurufocus.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual MeetingApril 7, 2025 | globenewswire.comBrokers Offer Predictions for TNXP Q1 EarningsApril 7, 2025 | marketbeat.comWhat is Zacks Small Cap's Forecast for TNXP FY2027 Earnings?April 5, 2025 | marketbeat.comTonix Pharmaceuticals (TNXP) Projected to Post Quarterly Earnings on MondayApril 5, 2025 | marketbeat.comTNXP: No AdCom Required for TNX-102 SL NDA…April 3, 2025 | finance.yahoo.comTonix Pharmaceuticals launches TONIX ONE digital platformApril 2, 2025 | markets.businessinsider.comTonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation ConferenceApril 2, 2025 | globenewswire.comTonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine ConditionApril 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatNVIDIA Stock: Oversold, Undervalued — How Low Can It Go?By Thomas Hughes | April 7, 2025View NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?Tesla Stock Eyes Breakout With Earnings on DeckBy Sam Quirke | April 16, 2025View Tesla Stock Eyes Breakout With Earnings on DeckNewsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?By Jeffrey Neal Johnson | April 6, 2025View Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?2 Defensive Sectors to Protect Your Portfolio During a RecessionBy Ryan Hasson | April 7, 2025View 2 Defensive Sectors to Protect Your Portfolio During a RecessionCHUC, TIL, TNXP, and SNTI Company DescriptionsCharlie's OTCMKTS:CHUC$0.11 +0.01 (+10.00%) As of 03:58 PM EasternCharlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.Senti Biosciences NASDAQ:SNTI$5.00 +0.13 (+2.67%) Closing price 04:00 PM EasternExtended Trading$4.89 -0.11 (-2.10%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Instil Bio NASDAQ:TIL$12.78 -6.83 (-34.83%) Closing price 04:00 PM EasternExtended Trading$13.20 +0.42 (+3.29%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Tonix Pharmaceuticals NASDAQ:TNXP$17.82 +0.63 (+3.66%) Closing price 04:00 PM EasternExtended Trading$17.32 -0.50 (-2.78%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
